Check Your Claims Before Reviewers Do

 Quick Explanation Copied

 Long Explanation

Profile overview. Ryan D. Beveridge shows h-index 14 with 1,148 total citations across 26 indexed papers, averaging ~44 citations per paper — respectable for translational molecular biology, where citation density is lower than in genomics or AI. Duplicate entries in the record (e.g., the CRISPR-Cas9 oxidative phosphorylation paper, the NP105-113 COVID paper, and MRNIP/C5orf45 appear twice) suggest the true unique paper count is closer to ~22, meaning metrics may be slightly inflated by indexing duplication.

Research trajectory and strengths. His early-career work is anchored in DNA damage response and genome stability — centriolar satellite proteins (Cep131, CCDC13), the MRN complex interactor MRNIP/C5orf45, UCHL3/TDP1 proteostasis, and Fanconi anaemia pathway involvement in glioma. This body overlaps with large collaborative resources (genome-wide knockout mouse phenotyping). He then pivoted to AML/ALL leukemia genetics — MLL-AF4/KMT2A-AFF1 regulatory networks and a notable neomorphic progenitor paper on C/EBPα/GATA-2 bilineage erythroid leukemia — before the 2020-2023 COVID era, where he co-authored mechanistic T cell work on proteasomal antigen processing of SARS-CoV-2 variants and an immunodominant HLA-B*07:02-restricted NP response linked to milder disease. Recent work on lentiviral vector production and low-pH CRISPR screens indicates applied bioprocessing and tumor microenvironment expansion.

Limitations and blindspots. No affiliation metadata was retrievable (OpenAlex returned a rate-limit error), so institutional context, grant portfolio, and h-index inflation from review articles cannot be independently verified. Citation counts are dominated by co-authored work; first/senior authorship positions are not visible from the metadata, and per-paper citation distributions (rather than totals) are unknown. The record lacks any single landmark paper with thousands of citations, which constrains the score.

 BGPT Author Review

Scientific Quality

h-index 14 with ~1,148 citations across ~22 unique papers reflects a competent, productive mid-career researcher with breadth across DNA damage, leukemia genomics, and antiviral T cell immunity. Strengths: participation in mechanistically clean, well-cited collaborative studies and a rare successful pivot across three fields. Weaknesses: no single landmark first-author paper, duplicated index entries, thin affiliation data, and citation metrics likely co-authorship-driven rather than a signal of independent leadership.

Communication Quality

Paper titles are precise, mechanistic, and accurately descriptive (e.g., proteasome processing altering CD8+ T cells), indicating clear scientific communication in writing. No evidence is available on talks, reviews, or mentoring, limiting confidence.

Author Novelty

Several papers are genuinely novel: the neomorphic neutrophil-erythroid progenitor in bilineage leukemia, identification of MRNIP/C5orf45, and demonstration that SARS-CoV-2 mutations alter proteasomal antigen processing are original contributions. Other work (CRISPR low-pH screens, VLP-cGAMP adjuvanting) is confirmatory/incremental within active fields.

Scientific Rigor

Titles indicate hypothesis-driven, mechanistic designs (CRISPR screens, gene regulatory networks, antigen processing assays) consistent with careful work. Rigor score is capped because per-study controls, replication, and statistical handling cannot be verified from metadata alone, and one low-citation output (UAV deployment paper) sits outside core expertise.